The British Business Bank has committed €25 million to EQT Life Sciences' EQT Health Economics 3 Fund, supporting high-potential life sciences companies in the UK. This investment is part of the Bank's ongoing efforts to back the UK's life sciences sector, one of the eight growth sectors of the UK Industrial Strategy. The fund will focus on commercial-stage, de-risked medtech and digital health technologies.

Contrary to popular belief, the surge of billion-dollar 'seed' rounds in AI doesn't guarantee venture-like returns. Drawing parallels with biotech's history of capital-intensive startups, new data suggests that only a tiny fraction of mega-funded first rounds deliver exceptional investor outcomes, challenging the perceived rewrite of the venture model.

Europe's tech ecosystem is witnessing a significant resurgence, with over €2.8 billion in funding deals reported this week, signaling a robust venture capital rebound. Major investments into hyperscalers like Nscale, deep tech pioneers such as Proxima Fusion, and strategic AI acquisitions underscore a growing confidence in the continent's innovation capacity and its pivotal role in the future of AI.

Crunchbase data reveals Q2 2026 delivered the most billion‑dollar startup exits since 2021, led by SpaceX’s historic $75B IPO and a wave of high‑value acquisitions. While the count lags the 2021 peak, the sheer size of these deals is reshaping the AI and tech investment landscape.